Skip to main content
Journal cover image

Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults.

Publication ,  Journal Article
Gostelow, M; Gonzalez, D; Smith, PB; Cohen-Wolkowiez, M
Published in: Expert Rev Clin Pharmacol
May 2014

Methicillin-resistant Staphylococcus aureus (MRSA) remains a significant cause of morbidity in hospitalized infants. Over the past 15 years, several drugs have been approved for the treatment of S. aureus infections in adults (linezolid, quinupristin/dalfopristin, daptomycin, telavancin, tigecycline and ceftaroline). The use of the majority of these drugs has extended into the treatment of MRSA infections in infants, frequently with minimal safety or dosing information. Only linezolid is approved for use in infants, and pharmacokinetic data in infants are limited to linezolid and daptomycin. Pediatric trials are underway for ceftaroline, telavancin, and daptomycin; however, none of these studies includes infants. Here, we review current pharmacokinetic, safety and efficacy data of these drugs with a specific focus in infants.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Expert Rev Clin Pharmacol

DOI

EISSN

1751-2441

Publication Date

May 2014

Volume

7

Issue

3

Start / End Page

327 / 340

Location

England

Related Subject Headings

  • Young Adult
  • Treatment Outcome
  • Staphylococcal Infections
  • Pharmacology & Pharmacy
  • Methicillin-Resistant Staphylococcus aureus
  • Infant
  • Humans
  • Drug Approval
  • Clinical Trials as Topic
  • Child, Preschool
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gostelow, M., Gonzalez, D., Smith, P. B., & Cohen-Wolkowiez, M. (2014). Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults. Expert Rev Clin Pharmacol, 7(3), 327–340. https://doi.org/10.1586/17512433.2014.909281
Gostelow, Martyn, Daniel Gonzalez, P Brian Smith, and Michael Cohen-Wolkowiez. “Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults.Expert Rev Clin Pharmacol 7, no. 3 (May 2014): 327–40. https://doi.org/10.1586/17512433.2014.909281.
Gostelow M, Gonzalez D, Smith PB, Cohen-Wolkowiez M. Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults. Expert Rev Clin Pharmacol. 2014 May;7(3):327–40.
Gostelow, Martyn, et al. “Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults.Expert Rev Clin Pharmacol, vol. 7, no. 3, May 2014, pp. 327–40. Pubmed, doi:10.1586/17512433.2014.909281.
Gostelow M, Gonzalez D, Smith PB, Cohen-Wolkowiez M. Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults. Expert Rev Clin Pharmacol. 2014 May;7(3):327–340.
Journal cover image

Published In

Expert Rev Clin Pharmacol

DOI

EISSN

1751-2441

Publication Date

May 2014

Volume

7

Issue

3

Start / End Page

327 / 340

Location

England

Related Subject Headings

  • Young Adult
  • Treatment Outcome
  • Staphylococcal Infections
  • Pharmacology & Pharmacy
  • Methicillin-Resistant Staphylococcus aureus
  • Infant
  • Humans
  • Drug Approval
  • Clinical Trials as Topic
  • Child, Preschool